Portal de Periódicos da CAPES

Appropriate Vitamin Therapy for Dialysis Patients

1997; Wiley; Volume: 10; Issue: 5 Linguagem: Inglês

10.1111/j.1525-139x.1997.tb00512.x

1525-139X

Michael V. Rocco, Rhoda Makoff,

Pharmacological Effects and Toxicity Studies

Seminars in DialysisVolume 10, Issue 5 p. 272-277 Appropriate Vitamin Therapy for Dialysis Patients Michael V. Rocco, Corresponding Author Michael V. Rocco Department of Medicine, Section of Nephrology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North CarolinaDepartment of Internal Medicine, Section on Nephrology, Medical Center Boulevard, Winston-Salem, NC 27157-1053Search for more papers by this authorRhoda Makoff, Rhoda Makoff R & D Laboratories, Inc., Marina del Rey, CaliforniaSearch for more papers by this author Michael V. Rocco, Corresponding Author Michael V. Rocco Department of Medicine, Section of Nephrology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North CarolinaDepartment of Internal Medicine, Section on Nephrology, Medical Center Boulevard, Winston-Salem, NC 27157-1053Search for more papers by this authorRhoda Makoff, Rhoda Makoff R & D Laboratories, Inc., Marina del Rey, CaliforniaSearch for more papers by this author First published: 01 October 2007 https://doi.org/10.1111/j.1525-139X.1997.tb00512.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Makoff R: Water-soluble vitamin status in patients with renal disease treated with hemodialysis or peritoneal dialysis. J Renal Nutr 1: 56–73, 1991. 2 Stein G, Sperschneider S, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3: 52–62, 1985. 3 Kasarna R, Koch T, Canais-Navas C, Pione JM: Vitamin B6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of the literature. Am J Kidney Dis 27: 680–686, 1996. 4 Muth I: Implications of hypervitaminosis A in chronic renal failure. J Renal Nutr 1: 1–8, 1991. 5 Rocco MV, Poole D, Poindexter P, Jordan J, Burkart JM: Intake of vitamins and minerals in stable hemodialysis patients as determined by nine-day food records. J Renal Nutr 7: 17–24, 1997. 6 The American Dietetic Association: A healthy Food Guide: Diabetes and Hemodialysis. National Renal Diet, 1993. 7 Allman MA, Truswell AS, Tiller DJ, Stewart PM, Yau DF, Horvath JS, Duggin GG: Vitamin supplementation of patients receiving hemodialysis. Med J Aust 150: 130–133, 1989. 8 Jennette JC, Goldman ID: Inhibition of the membrane transport of folates by anions retained in uremia. J Lab Clin Med 86: 834–843, 1975. 9 Lacour B, Parry C, Drueke T, et al.: Pyridoxal 5′-phosphate deficiency in uremic undialyzed, hemodialyzed and non-uremic kidney transplant patients. Clin Chim Acta 127: 205–215, 1983. 10 Waxman S, Corcino JJ, Herbert V: Drugs, toxins and dietary amino acids affecting vitamin B12 or folic acid absorption or utilization. Am J Med 48: 599–608, 1970. 11 Steiner A: The effect of choline on the production of experimental atherosclerosis in rabbits. Proc Soc Exp Biol Med 38: 231–233, 1938. 12 Hartroft WS, Ridout JH, Sellers EA, Best CH: Atheromatous changes in aorta, carotid and coronary arteries of choline deficient rats. Proc Soc Exp Biol Med 81: 384–393, 1952. 13 Robinson K, Mayer EL, Miller DP, et al.: Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 92: 2825–2830, 1995. 14 Nygàrd O, Vollset SE, Refsum H, et al.: Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 274: 1526–1533, 1995. 15 Fermo I, D'Angelo SV, Paroni R, Mazzola G, Calori G, D'Angelo A: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 123: 747–753, 1995. 16 Makoff R, Dwyer J, Rocco MV: Folic acid, pyridoxine, cobalamin and homocysteine and their relationship to cardiovascular disease in end-stage renal disease. J Renal Nutr 6: 2–11, 1996. 17 Bachmann J, Tepel M, Raidt H, Riezer R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121–125, 1995. 18 Kim SS, Hirose S, Tamura H, Nagasawa R, Tokushima H, Mitarai T, Isoda K: Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 10: 282–285, 1994. 19 Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40: 230–234, 1993. 20 Ubbink JB, Vermaak WJH, Van der Merwe A, et al.: Vitamin B12, vitamin B6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57: 47–53, 1993. 21 Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147–152, 1996. 22 Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultbert G, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40: 236–240, 1993. 23 Chauveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but no pyridoxine) supplementation lowers elevated plasma homocysteine levels in chronic renal failure. Mineral and Electrolyte Metabolism 22: 106–109, 1996. 24 Drueke TB: Resistance to recombinant human erythropoietin in hemodialysis patients. Am J Nephrol 10(suppl 2): 34–39, 1990. 25 Herbert V, Das KC: Folic acid and vitamin B12, in Modern Nutrition in Health and Disease, 8th edition, edited by ME Shills, JA Olson, M. Shike Philadelphia , Lea & Febiger, 1994, pp. 402–425. 26 Ono K, Hisasue Y: Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy Clin Nephrol 38: 290–292, 1992. 27 Mydik M, Derzsiova K: Erythrocyte vitamins B1, B2 and B6 and erythropoietin. Am J Nephrol 13: 464–466, 1993. 28 Zachee P, Chew S, Daelemans R, Lins RL: Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythrocyte treatment. Am J Nephrol 12: 188–191, 1992. 29 Gotloib L, Servadio C: A possible case of beriberi heart failure in a chronic hemodialyzed patient. Nephron 14: 293–298, 1975. 30 Bastow MD, Woods HF, Walls J: Persistent anemia associated with reduced serum vitamin B12 levels in patients undergoing regular hemodialysis therapy. Clinical Nephrology 11: 133–135, 1979. 31 Ihle BU, Gillies M: Scurvy and thrombocytopathy in a chronic hemodialysis patient. Aust NZ J Med 13: 523, 1983. 32 Sullivan JF, Eisenstein AB: Ascorbic acid depletion in patients during hemodialysis. Am J Clin Nutr 23: 1339–1346, 1970. 33 Tomson CRV, Channon SM, Parkinson IS, McArdie P, Qureshi M, Ward MK, Laker MF: Correction of subclinical ascorbate deficiency in patients receiving dialysis: Effects on plasma oxalate, serum cholesterol, and capillary fragility. Clinica Chimica Acta 180: 255–264, 1989. 34 Hemmeløff Andersen KE: Folic acid status of patients with chronic renal failure maintained by dialysis. Clin Nephrol 8: 510–513, 1977. 35 Westhuyzen J, Materson K, Tracey R, Fleming SJ: Effect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 40: 4096–4099, 1993. 36 Stone WJ, Warnock LG, Wagner C: Vitamin B6 deficiency in uremia. Am J Clin Nutr 28: 950–957, 1975. 37 Descombes E, Hanck A, Fellay G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 43: 1319–1328, 1993. 38 Kleiner MJ, Tate SS, Sullivan JF, Chami J: Vitamin B6 deficiency in maintenance dialysis patients: Metabolic effects of repletion. Am J Clin Nutr 33: 1612–1619, 1980. 39 Kopple JD, Mercuio K, Blumendrantz MJ, et al.: Daily requirements for pyridoxine supplementation in chronic renal failure. Kidney Int 19: 694–704, 1981. 40 Ross EA, Shah GM, Reynolds RD, Sabo A, Pichon M: Vitamin B6 requirements of patients on chronic peritoneal dialysis. Kidney Int 36: 702–706, 1989. 41 Rosner F, Schreibner ZA: Serum vitamin B12 and Vitamin B12 binding capacity in chronic myelogenous leukemia and other disorders. Am J Med Sci 263: 473–480, 1972. 42 Pönka A, Kuhlbäck B: Serum ascorbic acid in patients undergoing chronic hemodialysis. Acta Medica Scandinavia 213: 305–307, 1983. 43 Papastephanidis C, Agroyannis B, Tzanatos-Exarchou H, et al: Reevaluation of ascorbic acid deficiency in hemodialysed patients. Intl J Artif Organs 10: 163–165, 1987. 44 Rolton HA, McConnell KM, Modi KS, Macdougall AI: The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis. Nephrol Dial Transplant 6: 440–443, 1991. 45 Ono K: Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients. Clin Nephrol 26: 239–243, 1986. 46 Shah GM, Ross EAL, Sabo A, et al.: Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients. Am J Kidney Dis 20: 42–49, 1992. 47 Morgan SH, Maher ER, Purkiss P, et al.: Oxalate metabolism in end-stage renal disease: The effects of ascorbic acid and pyridoxine. Nephrol Dial Transplant 3: 28–32, 1988. 48 Kopple J: Nutrition, diet, and the kidney, in Modern Nutrition in Health and Disease, 8th edition edited by ME Shills, JA Olson, M. Shike Philadelphia , Lea & Febiger Malvern, 1994, pp. 1102–1134. 49 Thompson CS, Weinman EJ: The secondary oxalosis of renal failure. Semin Dial 1: 94–99, 1988. 50 Celasun B, Safali M, Yenicesu M: Secondary oxalosis of bone in a dialysis patient. Scand J Urol Nephrol 29: 211–214, 1995. 51 Costello J, Landwehr DM: Determination of oxalate concentration in blood. Clin Chem 34: 1540–1544, 1988. 52 Costello JF, Sadovnic MJ, Cottington EM: Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1: 1289–1298, 1991. 53 Kopple JD, Swenseid ME: Nutrition in patients undergoing maintenance hemodialysis. Kidney Int 8 (suppl 2): 79–84, 1975. 54 Paskalev D, Jankova T, Tschankova P, Steiner M, Nenov D: Increase of plasma and red blood cell vitamin E concentration in uraemic patients on maintenance undergoing treatment with recombinant erythropoietin (letter). Nephrol Dial Transpl 8: 1187–1188, 1993. 55 Johnson KS, Hendricks DG, Wyse BW: Vitamin A and vitamin E status of hemodialysis patients. Dial Transplant 12: 477–482, 1983. 56 Yatzidis H, Digenis P, Fountas P: Hypervitaminosis A accompanying advanced chronic renal failure. Brit Med J 3: 352–353, 1975. 57 Praga M, Diaz Rubio P, Morales JM, Cañizares F, Ruilope LM, Gutierrez-Millet V, Nieto J, Rodicio JL: Implications of hypervitaminosis A on the calcium-phosphate metabolism and on blood lipids in hemodialysis. Am J Nephrol 7: 281–286, 1987. 58 Ellis S, DePalma J, Cheng A, Capozzalo P, Dombeck D, DiScala VA: Vitamin A supplements in hemodialysis patients. Nephron 26: 215–218, 1980. 59 Farrington K, Miller P, Varghese Z, Baillod RA, Moorhead JF: Vitamin A toxicity and hypercalcemia in chronic renal failure. Brit Med J 282: 1999–2002, 1981. 60 Gleghorn E, Eisenberg L, Hack S, et al.: Observations of vitamin A toxicity in three patients with renal failure receiving parenteral alimentation. Am J Clin Nutr 44: 107–112, 1986. 61 Fishbane S, Frei GL, Finger M, et al.: Hypervitaminosis A in two hemodialysis patients. Am J Kidney Dis 25: 346–349, 1995. 62 Duffy T: Remember the ABCs. New Engl J Med 330: 994–996, 1994. 63 DeBevere VO, Nelis HJ, DeLeenheer AP, Lambert WE, DePaepe M, Ringoir S: Vitamin E levels in hemodialysis patients. (letter) JAMA 247: 2371, 1982. 64 Pastor MC, Sierra C, Bonal J, Teixido J: Serum and erythrocyte tocopherol in uremic patients: Effect of hemodialysis versus peritoneal dialysis. Am J Nephrol 13: 238–243, 1993. 65 Cohen JD, Vilijoen M, Clifford D, De Oliveira AA, Veriava Y, Milne FJ: Plasma vitamin E levels in a chronically hemolyzing group of dialysis patients. Clin Nephrol 25: 42–47, 1986. 66 Ono K: Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 40: 440–445, 1985. 67 Lubrano R, Taccone-Gallucci M, Piazza A, et al.: Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients. Nutrition 8: 94–97, 1992. 68 Roca AO, Jarjoura D, Blend D, Cugino A, Rutecki GW, Nuchikat PS. Whittier FC: Dialysis leg cramps. Efficacy of quinine versus vitamin E. ASAIO J 38: M481–485, 1992. 69 American Dietetic Association: A Clinical Guide to End Stage Renal Disease, 2nd ed., 1994, pp. 28–34. 70 Roberts HJ: Perspective on vitamin E as therapy. JAMA 246: 129–131, 1981. 71 Suttie JW: Vitamin K, in Handbook of Vitamins, 2nd edition, edited by LJ. Machlin New York , Marcel Dekker, 1991, pp. 145–194. 72 Olson RE: Vitamin K, in Hemostasis and Thrombosis, 2nd edition, edited by RW Colman, J Hirsh, VJ Marder, EW Salzman. Philadelphia . JB Lippincott, 1987, pp. 846–860. 73 Fukagawa M, Kitaoka M, Fukada N, Yi H, Kurokawa K: Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: Role of calcitriol. Mineral Electrolyte Metabolism 21: 97–100, 1995. 74 Llach F: Secondary hyerparathyroidism in renal failure: The trade-off hypothesis revisited. Am J Kidney Dis 25: 663–679, 1995. Citing Literature Volume10, Issue5September 1997Pages 272-277 ReferencesRelatedInformation